Litchfield Hills Research Weighs in on ADIL Q1 Earnings

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Investment analysts at Litchfield Hills Research boosted their Q1 2025 EPS estimates for Adial Pharmaceuticals in a report issued on Tuesday, March 18th. Litchfield Hills Research analyst T. O’neill now anticipates that the company will earn ($0.37) per share for the quarter, up from their previous estimate of ($0.40). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.22) EPS.

Adial Pharmaceuticals (NASDAQ:ADIL) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.23.

Adial Pharmaceuticals Stock Down 1.7 %

ADIL opened at $0.72 on Thursday. The stock has a market cap of $4.76 million, a PE ratio of -0.22 and a beta of 1.13. Adial Pharmaceuticals has a 52 week low of $0.61 and a 52 week high of $3.10. The business’s fifty day simple moving average is $0.83 and its 200 day simple moving average is $0.97.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ADIL. Renaissance Technologies LLC bought a new position in Adial Pharmaceuticals in the fourth quarter valued at $48,000. Citadel Advisors LLC increased its stake in Adial Pharmaceuticals by 63.8% in the fourth quarter. Citadel Advisors LLC now owns 54,508 shares of the company’s stock valued at $55,000 after acquiring an additional 21,238 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Adial Pharmaceuticals by 36.0% in the fourth quarter. Geode Capital Management LLC now owns 61,847 shares of the company’s stock valued at $62,000 after acquiring an additional 16,381 shares during the last quarter. Institutional investors own 16.41% of the company’s stock.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.